abstract |
Described is an isolated human anti-TNFalpha antibody (D2E7, adalimumab) for use in the treatment of mild to severe rheumatoid arthritis in a human subject, wherein the antibody is for subcutaneous administration to a human subject in a 2-week dosing regimen of 40 mg every 14 days and the antibody is for administration in combination methotrexate. |